Clinical Trial Update: A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Fruquintinib plus FOLFIRI as second-line therapy for metastatic colorectal cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Fruquintinib (fruquintinib)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Colon Cancer, Rectal Cancer | Phase 2 | Status: RECRUITING